Posted by Michael Wonder on 22 Feb 2022
BeiGene announces U.S. FDA acceptance of supplemental new drug application for Brukinsa (zanubrutinib) in chronic lymphocytic leukaemia
22 February 2022 - The Prescription Drug User Fee Act target action date is 22 October 2022.
BeiGene today announced that the U.S. FDA has accepted a supplemental new drug application for Brukinsa (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma.
